Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172633 | 1.00 | SIGMAR1 (0.70) | SIGMAR1POLBLTA4HBCHELMNA | |
| SCHEMBL172363 | 1.00 | SIGMAR1 (0.70) | SIGMAR1POLBLTA4HBCHELMNA | |
| SCHEMBL10943350 | 0.89 | SIGMAR1 (0.54) | SIGMAR1LTA4HBCHECYP3A4SMN1; SMN2 | |
| SCHEMBL13200644 | 0.85 | SIGMAR1 (0.52) | SIGMAR1LTA4HCYP3A4SMN1; SMN2 | |
| SCHEMBL8826024 | 0.84 | SIGMAR1 (0.51) | SIGMAR1LTA4HBCHEKDM4ESMN1; SMN2 | |
| SCHEMBL8691568 | 0.84 | SIGMAR1 (0.51) | SIGMAR1LTA4HBCHEKDM4ESMN1; SMN2 | |
| SCHEMBL8692762 | 0.84 | SIGMAR1 (0.51) | SIGMAR1LTA4HBCHEKDM4ESMN1; SMN2 | |
| SCHEMBL172531 | 0.83 | SIGMAR1 (0.66) | SIGMAR1POLBBCHELMNATAAR1 | |
| N-Benzylamphetamine SCHEMBL2451256 | 0.83 | SIGMAR1 (1.00) | SIGMAR1POLBLMNATAAR1SLC18A2 | |
| N-Benzylamphetamine SCHEMBL2795222 | 0.83 | SIGMAR1 (1.00) | SIGMAR1POLBLMNATAAR1SLC18A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252694-A1 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS | RAYZEBIO, INC. | 2024-08-01 | — | — | US | disclosed |
| US-11753418-B2 | Compounds for the modulation of Myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753418-B2 | Compounds for the modulation of Myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753418-B2 | Compounds for the modulation of Myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220048927-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-02-17 | — | — | US | disclosed |
| US-11124527-B2 | Compounds for the modulation of Myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124527-B2 | Compounds for the modulation of Myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20180354972-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-12-13 | — | — | US | disclosed |
| WO-2016196910-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196910-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-7601842-B2 | Method for producing an optically active tetrahydroquinoline | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20090208942-A1 | Method and Apparatus for Correlating Levels of Biomarker Products with Disease | GENENEWS INC. (CA) | 2009-08-20 | — | — | US | disclosed |
| WO-2008030902-A1 | ALKYLENE BRIDGED SULTAM COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753418-B2 | Compounds for the modulation of Myc activity | MYC, MYCBP, MYCBP2 | SIGMAR1 4177/4885POLB 1570/4885LTA4H 2595/4885 |
| US-20220048927-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | SIGMAR1 4177/4885POLB 1570/4885LTA4H 2595/4885 |
| US-20240252694-A1 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS | KRAS, NRAS, HRAS | SIGMAR1 4530/4885POLB 3641/4885LTA4H 4659/4885 |
| US-20180354972-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | SIGMAR1 4177/4885POLB 1570/4885LTA4H 2595/4885 |
| US-11124527-B2 | Compounds for the modulation of Myc activity | MYC, MYCBP, MYCBP2 | SIGMAR1 4177/4885POLB 1570/4885LTA4H 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.